Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
View original at finance.yahoo.comOlema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Olema Oncology On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
Palazestrant has potential as the combination endocrine therapy of choice in the metastatic setting
60% confidenceCommercial launch preparations are underway for a potential approval in late 2027
60% confidenceTop-line data from OPERA-01 is expected in the fall of 2026
60% confidenceTransformation into a fully-integrated oncology company is underway in preparation for the Company's first potential commercial launch in late 2027
60% confidenceInitial clinical results from OP-3136 are anticipated in Q2 2026
60% confidence2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens
60% confidenceThe November 2025 public offering enables funding operations through numerous expected value-creating events with palazestrant
60% confidenceOlema is on-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial
60% confidence